INTRODUCTION
An excess of submental fat (SMF) can lead to an unappealing submental profile and poor jawline definition, thus affecting the overall appearance of the face.1 As a result, individuals may seek aesthetic treatments for improving submental convexity and jawline contour.1,2 ATX-101 (deoxycholic acid injections; Kybella [US]/Belkyra [Canada, Australia, Europe, and South Korea]; Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA) is a cytolytic agent that causes lysis of adipocytes and is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with SMF.3-7 In the ATX-101 phase 3 trials, skin laxity did not worsen and even showed improvements (ie, less wrinkling/lines, adherence to underlying structures) in the majority of participants despite reductions in SMF.5,6,8 These results suggest that local inflammatory responses following ATX-101 treatment may induce neocollagenesis.8,9
A phase 4, prospective, open-label, multicenter, interventional study showed that sequential treatment using ATX-101 followed by VYC-20L (Juvederm Voluma with Lidocaine, Allergan Aesthetics), a hyaluronic acid (HA) filler used to restore facial volume in the midface10,11 and structurally support the chin,12,13 reduced SMF, and improved jawline definition.14 Most of the participants (92.9%) achieved 1-point or greater improvement from
A phase 4, prospective, open-label, multicenter, interventional study showed that sequential treatment using ATX-101 followed by VYC-20L (Juvederm Voluma with Lidocaine, Allergan Aesthetics), a hyaluronic acid (HA) filler used to restore facial volume in the midface10,11 and structurally support the chin,12,13 reduced SMF, and improved jawline definition.14 Most of the participants (92.9%) achieved 1-point or greater improvement from